



# Acute Respiratory Distress Syndrome (ARDS) and What You Should Know

Tim Gilmore, PhD, RRT, RRT-ACCS, RRT-NPS, CPFT, AE-C  
Associate Professor  
Cardiopulmonary Science Program  
Louisiana State University Health  
Shreveport, Louisiana

Conflict of Interest: **None**


*I have no perceived conflicts of interest  
and am not affiliated with any  
pharmaceutical, equipment, or  
manufacturing company.*

# Learning Objectives

As a result of this course, participants will be able to:

- 1) **Define and describe** acute respiratory distress syndrome in alignment with current Berlin criteria.
- 2) **Classify** ARDS
- 3) **Develop evidence-based** mechanical ventilation **strategies** as part of ARDS treatment

# Acute Respiratory Distress Syndrome




Ashbaugh, D., Boyd Bigelow, D., Petty, T., & Levine, B. (1967). ACUTE RESPIRATORY DISTRESS IN ADULTS. *The Lancet*, 290(7511), 319-323.

**Summary** The respiratory-distress syndrome in 12 patients was manifested by acute onset of tachypnoea, hypoxaemia, and loss of compliance after a variety of stimuli; the syndrome did not respond to usual and ordinary methods of respiratory therapy. The clinical and pathological features closely resembled those seen in infants with respiratory distress and to conditions in congestive atelectasis and postperfusion lung. The theoretical relationship of this syndrome to alveolar surface active agent is postulated. Positive end-expiratory pressure was most helpful in combating atelectasis and hypoxaemia. Corticosteroids appeared to have value in the treatment of patients with fat-embolism and possibly viral pneumonia.

# ARDS Defined

- **1967**
  - First described (*The Lancet*)
- Late 1960's – early 1990's
  - various iterations of descriptions and definitions
  - no formal consensus
  - (1988) expanded definition proposed
- **1994**
  - American-European Consensus Conference formal definition
- **2011**
  - **Berlin definition** established



ONLINE FIRST

# Acute Respiratory Distress Syndrome

## The Berlin Definition

**Table 3.** The Berlin Definition of Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome	
Timing	Within 1 week of a known clinical insult or new or worsening respiratory symptoms
Chest imaging <sup>a</sup>	Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules
Origin of edema	Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
Oxygenation <sup>b</sup>	
Mild	200 mm Hg < PaO <sub>2</sub> /F <sub>IO</sub> <sub>2</sub> ≤ 300 mm Hg with PEEP or CPAP ≥5 cm H <sub>2</sub> O <sup>c</sup>
Moderate	100 mm Hg < PaO <sub>2</sub> /F <sub>IO</sub> <sub>2</sub> ≤ 200 mm Hg with PEEP ≥5 cm H <sub>2</sub> O
Severe	PaO <sub>2</sub> /F <sub>IO</sub> <sub>2</sub> ≤ 100 mm Hg with PEEP ≥5 cm H <sub>2</sub> O


Abbreviations: CPAP, continuous positive airway pressure; F<sub>IO</sub><sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

<sup>a</sup>Chest radiograph or computed tomography scan.

<sup>b</sup>If altitude is higher than 1000 m, the correction factor should be calculated as follows: [PaO<sub>2</sub>/F<sub>IO</sub><sub>2</sub> × (barometric pressure/760)].

<sup>c</sup>This may be delivered noninvasively in the mild acute respiratory distress syndrome group.

ARDS is a clinical “syndrome” usually a **result of** an insult such as **infection or trauma**




# ARDS

## Nomenclature

- **Acute Respiratory Distress Syndrome**
  - Acute Lung Injury?
- “Adult” Respiratory Distress Syndrome
- “Wet Lung”; “Shock Lung”
- *Severe* Respiratory Distress Syndrome


*“Baby Lung”*



# ARDS

## Clinical features

- Progressive dyspnea with increasing O<sub>2</sub> requirements
- Alveolar infiltrates on chest x-ray & reduced SaO<sub>2</sub> (SpO<sub>2</sub>) within 6-72h of inciting event
- Lab tests are nonspecific



# ARDS

## CRITICAL CARE PERSPECTIVE

FIFTY YEARS OF RESEARCH IN ARDS

**The Epidemiology of Acute Respiratory Distress Syndrome**

A 50th Birthday Review

Tài Pham<sup>1,2</sup> and Gordon D. Rubenfeld<sup>1,3</sup>

<sup>1</sup>Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada; <sup>2</sup>Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; and <sup>3</sup>Program in Trauma, Emergency, and Critical Care Organization, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada

Here's what we know...



Official Publications of the  
American Thoracic Society

**Minimizing ventilator-induced lung injury  
is likely most effective in treating ARDS**

# LUNG-SAFE

JAMA | **Original Investigation** | CARING FOR THE CRITICALLY ILL PATIENT

## Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

Giacomo Bellani, MD, PhD; John G. Laffey, MD, MA; Tàì Pham, MD; Eddy Fan, MD, PhD; Laurent Brochard, MD, HDR; Andres Esteban, MD, PhD; Luciano Gattinoni, MD, FRCP; Frank van Haren, MD, PhD; Anders Larsson, MD, PhD; Daniel F. McAuley, MD, PhD; Marco Ranieri, MD; Gordon Rubinfeld, MD, MSc; B. Taylor Thompson, MD, PhD; Hermann Wrigge, MD, PhD; Arthur S. Slutsky, MD, MASc; Antonio Pesenti, MD; for the LUNG SAFE Investigators and the ESICM Trials Group


**CONCLUSIONS AND RELEVANCE** Among ICUs in 50 countries, the period prevalence of ARDS was 10.4% of ICU admissions. This syndrome appeared to be underrecognized and undertreated and associated with a high mortality rate. These findings indicate the potential for improvement in the management of patients with ARDS.

# The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019

Kathryn W. Hendrickson, MD<sup>a,b</sup>, Ithan D. Peltan, MD, MSc<sup>a,c</sup>,  
Samuel M. Brown, MD, MS<sup>a,b,\*</sup>

Crit Care Clin. 2021 Oct;37(4):703-716

COVID-19-associated ARDS is a syndrome on the ARDS spectrum and should therefore be treated with the same strategies as classic ARDS while we await results of ongoing trials.



## Etiology of acute respiratory distress syndrome\*

Etiology	Clinical features	Diagnostic tests
Sepsis	Fever, hypotension, leukocytosis, lactic acidosis, infectious source	Appropriate clinical context and positive cultures
Aspiration pneumonitis	Witnessed or risk for aspiration, food, lipid laden macrophages, airway erythema on bronchoscopy	Presumptive diagnosis with negative cultures
Infectious pneumonia (including mycobacterial, viral, fungal, parasitic)	Productive cough, pleuritic pain, fever, leukocytosis, lobar consolidation or bilateral infiltrates in an immunosuppressed patient	Appropriate clinical context and positive respiratory cultures
Severe trauma and/or multiple fractures	History of trauma or fractures within the last week	Diagnosis is apparent
Pulmonary contusion	History of chest trauma (blunt or penetrating), chest pain	Presumptive diagnosis in the correct clinical context, negative cultures
Burns and smoke inhalation	Exposure to fire or smoke, cough, dyspnea, DIC, particulate matter on bronchoscopy, surface burns	Presumptive diagnosis in the correct clinical context, negative cultures
Transfusion related acute lung injury and massive transfusions	History of transfusion, dyspnea during or shortly after transfusion	Diagnosis of exclusion
HSCT <sup>†</sup>	History of HSCT	Diagnosis of exclusion
Pancreatitis	Abdominal pain, vomiting, risk factors (eg, gallstones, alcohol, viral infection)	Elevated amylase and lipase, with or without abnormal imaging
Inhalation injures other than smoke (eg, near drowning, gases)	History of inhalation exposure (eg, chlorine gas)	Diagnosis of exclusion
Thoracic surgery (eg, post-cardiopulmonary bypass) or other major surgery	History of surgery, intraoperative ventilation, intraoperative transfusion	Diagnosis of exclusion
Drugs (chemotherapeutic agents, amiodarone, radiation)	New drugs or radiation exposure on history, lymphocytosis on lavage, lavage may have suggestive features of amiodarone toxicity ("foamy macrophages") but is nonspecific	Diagnosis of exclusion, lung biopsy occasionally helpful



Chest radiograph showing diffuse, bilateral, alveolar infiltrates without cardiomegaly in a patient with ARDS.

---

ARDS: acute respiratory distress syndrome.

---

*Courtesy of Steven E Weinberger, MD.*



ARDS due to sepsis after pneumococcal pneumonia.

---

ARDS: acute respiratory distress syndrome; CT: computed tomography.

---



*Courtesy of Paul Stark, MD.*

# Stages of ARDS

**Early Exudative Stage (Early)**

**Fibroproliferative Stage (Mid)**

**Fibrotic Stage (Later)**



# RESPIRATORY CARE

## Past and Present ARDS Mortality Rates: A Systematic Review

Jan Máca MD, Ondřej Jor MD, Michal Holub MD PhD, Peter Sklienka MD,  
Filip Burša MD PhD, Michal Burda PhD, Vladimír Janout MD CSc,  
and Pavel Ševčík MD CSc

Table 5. Absolute Values of the Most Recent Mortality Rates, Since 2010

Mortality Type	Retrospective		Prospective		RCTs		All	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
In-hospital	345	50	759	47	1,060	41	2,164	45
ICU	547	33	340	46	898	39	1,785	38
28/30-d	1,068	26	606	34	832	31	2,506	30
60-d	751	33	1,294	38	858	23	2,903	32

Retrospective = retrospective observational studies  
Prospective = prospective observational studies  
RCTs = randomized controlled trials


ARDS-  
related  
**mortality**  
rates remain  
**high**

RESEARCH

Open Access

# Causes and characteristics of death in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: a retrospective cohort study



Scott W. Ketcham<sup>1\*</sup> , Yub Raj Sedhai<sup>1</sup>, H. Catherine Miller<sup>1</sup>, Thomas C. Bolig<sup>1</sup>, Amy Ludwig<sup>1</sup>, Ivan Co<sup>1,2</sup>, Dru Claar<sup>1</sup>, Jakob I. McSparron<sup>1</sup>, Hallie C. Prescott<sup>1,3,4</sup> and Michael W. Sjoding<sup>1,3</sup>

**Results:** We identified 385 decedents with AHRF, of whom 127 (33%) had ARDS. The most common primary causes of death were sepsis (26%), pulmonary dysfunction (22%), and neurologic dysfunction (19%). Multi-organ failure was present in 70% at time of death, most commonly due to sepsis (50% of all patients), and 70% were on significant respiratory support at the time of death. Only 2% of patients had insupportable oxygenation or ventilation. Eighty-five percent died following withdrawal of life support. Patients with ARDS more often had pulmonary dysfunction as the primary cause of death (28% vs 19%;  $p = 0.04$ ) and were also more likely to die while requiring significant respiratory support (82% vs 64%;  $p < 0.01$ ).

(Continued on next page)

ONLINE FIRST

# Acute Respiratory Distress Syndrome

## The Berlin Definition

**Table 3.** The Berlin Definition of Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome	
Timing	Within 1 week of a known clinical insult or new or worsening respiratory symptoms
Chest imaging <sup>a</sup>	Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules
Origin of edema	Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
Oxygenation <sup>b</sup>	
Mild	200 mm Hg < PaO <sub>2</sub> /F <sub>IO</sub> <sub>2</sub> ≤ 300 mm Hg with PEEP or CPAP ≥5 cm H <sub>2</sub> O <sup>c</sup>
Moderate	100 mm Hg < PaO <sub>2</sub> /F <sub>IO</sub> <sub>2</sub> ≤ 200 mm Hg with PEEP ≥5 cm H <sub>2</sub> O
Severe	PaO <sub>2</sub> /F <sub>IO</sub> <sub>2</sub> ≤ 100 mm Hg with PEEP ≥5 cm H <sub>2</sub> O

Abbreviations: CPAP, continuous positive airway pressure; F<sub>IO</sub><sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

<sup>a</sup>Chest radiograph or computed tomography scan.

<sup>b</sup>If altitude is higher than 1000 m, the correction factor should be calculated as follows: [PaO<sub>2</sub>/F<sub>IO</sub><sub>2</sub> × (barometric pressure/760)].

<sup>c</sup>This may be delivered noninvasively in the mild acute respiratory distress syndrome group.


# Redefining ARDS: a paradigm shift

Jesús Villar<sup>1,2,3\*</sup>, Tamas Szakmany<sup>4,5</sup>, Giacomo Grasselli<sup>6,7</sup> and Luigi Camporota<sup>8,9</sup>

$$P/F \text{ ratio} = \frac{P_aO_2}{F_I O_2}$$

**Table 1** Limitations of the current definition and diagnostic/therapeutic approach of ARDS

Bilateral and diffuse pulmonary edema	<ul style="list-style-type: none"> <li>Lack of a marker of non-cardiogenic origin of pulmonary edema</li> <li>Lack of a (bio)marker of pulmonary vascular permeability</li> </ul>
Oxygenation	<ul style="list-style-type: none"> <li>A single measurement of PaO<sub>2</sub>/FiO<sub>2</sub> at ARDS onset or diagnosis has poor performance for definition or predicting severity</li> <li>Lack of standardization of respiratory support settings for measuring PaO<sub>2</sub>/FiO<sub>2</sub></li> <li>Difficult to distinguish ARDS from acute hypoxemic respiratory failure since clinical features and etiologic causes are similar</li> </ul>
Lung mechanics	<ul style="list-style-type: none"> <li>Not required in the current definition</li> <li>Missing dead space (VD/VT) measurement in definition and progression</li> <li>Hard to conceive a mechanically ventilated ARDS patient receiving PEEP ≤ 5 cmH<sub>2</sub>O</li> </ul>
Systemic inflammation	<ul style="list-style-type: none"> <li>Definition and categorization do not account for non-pulmonary organ failure, which is present in most patients and a major determinant of outcome</li> <li>Too much emphasis on the alveolar side. Little consideration for the pulmonary vascular and endothelial side, presence of pulmonary hypertension or right ventricular function</li> <li>Systemic inflammation seen in ARDS based on protein and mRNA biomarkers is not specific for ARDS, especially in septic patients</li> </ul>
Categorization and sub-phenotyping	<ul style="list-style-type: none"> <li>Missing stratification in sub-phenotypes based on VD/VT, endothelial injury, biomarker levels, or modifiable or treatable traits</li> <li>It is highly plausible that in a substantial proportion of patients in recent trials, the severity of lung injury was modest</li> </ul>
Mechanical ventilation setting	<ul style="list-style-type: none"> <li>It should be personalized based on etiology, lung physiology, imaging and morphology, and clinical and biological classes or subclasses</li> <li>In some ARDS trials, unselected patients could be enrolled missing the opportunity to test whether the experimental MV approach is beneficial due to lack of standardized assessment of severity prior to randomization and to lack of patient sub-phenotyping</li> </ul>




# Redefining ARDS: a paradigm shift

Jesús Villar<sup>1,2,3\*</sup>, Tamas Szakmany<sup>4,5</sup>, Giacomo Grasselli<sup>6,7</sup> and Luigi Camporota<sup>8,9</sup>

**Table 2** Potential recommendations for improving the definition of ARDS

New datasets	1. Expiration date for observational studies and trials conducted before year 2010
Actionable criteria	2. Definition should be based on actionable and modifiable criteria, including VD/VT, lung imaging, biomarker levels, etc.
PaO <sub>2</sub> /FiO <sub>2</sub>	3. It should be assessed under standardized conditions (e.g., measured at predefined FiO <sub>2</sub> and PEEP levels)
Measures of severity	4. Categorization may include the threshold of 150 mmHg (< 150, ≥ 150)
	Two measures of "true" severity of ARDS:
Enrichment strategies	5. Lung injury per se: "Severe" ARDS should not be based only on PaO <sub>2</sub> /FiO <sub>2</sub>
	6. Severity of patient illness, including comorbidities and frailty
Pulmonary circulation	7. Prediction or prognostic enrichment strategies for inclusion of patients into therapeutic clinical trials. The use of artificial intelligence techniques may help
	8. More precise information about the anatomic/physiologic state of the pulmonary vascular circulation
Stratification, classification, or sub-phenotyping	9. An updated definition requires a new categorization or classification of severity based on gas-exchange, lung imaging, VD/VT, biomarker levels, use of non-invasive mechanical ventilation, degree of vascular permeability
	10. Excessive broadening of criteria required to diagnose ARDS should be avoided
Broadening definition	11. Recommendations for management and treatment in the new updated ARDS definition should be implemented by International Professional Societies
International professional societies	12. Implementation of a "Surviving ARDS (including patients at risk for) Campaign" with frequent updates
Implementation	

ARDS, acute respiratory distress syndrome; VD/VT, dead space



Ok, Ok.... We're sure it's ARDS, now what...?



Clin Chest Med 27 (2006) 725-731

CLINICS  
IN CHEST  
MEDICINE

## Why Do Patients Who Have Acute Lung Injury/Acute Respiratory Distress Syndrome Die from Multiple Organ Dysfunction Syndrome? Implications for Management

Jean-Louis Vincent, MD, PhD\*, Massimo Zambon, MD

Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, 1070 Brussels, Belgium

## Acute respiratory distress syndrome and multiple organ failure

Lorenzo Del Sorbo<sup>a</sup> and Arthur S. Slutsky<sup>b,c</sup>

<sup>a</sup>Dipartimento di Anestesia e Terapia Intensiva, Azienda Ospedaliera San Giovanni Battista, Università di Torino, Italy, <sup>b</sup>Keenan Research Center at the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Interdepartmental Division of Critical Care, Division of Respiratory Medicine, University of Toronto, Toronto, Ontario, Canada and <sup>c</sup>King Saud University, Riyadh, Saudi Arabia

Correspondence to Lorenzo Del Sorbo  
Tel: +39 011 633 5502;  
e-mail: lorenzodelsorbo@unito.it

Current Opinion in Critical Care 2011,  
17:1-6

### Purpose of review

Despite improvements in outcome due to lung protective ventilation strategies using low tidal volumes, the mortality rate from acute respiratory distress syndrome (ARDS) remains unacceptably high, ranging from 34 to 64%. The predominant cause of death in ARDS is not severe hypoxemia, which is one of the defining criteria of ARDS, but multiple organ failure (MOF).

### Recent findings

In view of the relationship between ARDS and MOF, two different but complementary pathophysiological perspectives will be developed in this article: ARDS as a consequence of MOF, and ARDS as the cause of MOF. This framework may be useful in guiding the development of novel therapeutic strategies that ultimately improve the

## Characteristics of Nonpulmonary Organ Dysfunction at Onset of ARDS Based on the Berlin Definition

Richard H Kallet, Michael S Lipnick, Hanjing Zhuo, Lance P Pangilinan, and Antonio Gomez

Ketcham et al. *Critical Care* (2020) 24:391  
<https://doi.org/10.1186/s13054-020-03108-w>

Critical Care

RESEARCH

Open Access



## Causes and characteristics of death in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: a retrospective cohort study

Scott W. Ketcham<sup>1\*</sup>, Yub Raj Sedhai<sup>1</sup>, H. Catherine Miller<sup>1</sup>, Thomas C. Bolig<sup>1</sup>, Amy Ludwig<sup>1</sup>, Ivan Co<sup>1,2</sup>, Dru Claar<sup>1</sup>, Jakob I. McSparron<sup>1</sup>, Hallie C. Prescott<sup>1,3,4</sup> and Michael W. Sjoding<sup>1,3</sup>



## clinical implications of basic research

### Mechanisms of Multiple Nonpulmonary Organ Failure in ARDS\*

Paul M. Dorinsky, M.D., F.C.C.P.; and James E. Gadek, M.D., F.C.C.P.

### **Mechanical Ventilation in ARDS\***

#### **A State-of-the-Art Review**



*Timothy D. Girard, MD; and Gordon R. Bernard, MD, FCCP*

- ✓ **Low tidal volume strategies (less than 6 mls/kg predicted body weight)**
  - ✓ **Maintain plateau below 30 cmH2O**
- ✓ **High PEEP**
- ✓ **Alveolar recruitment maneuvers**
- ✓ **Prone positioning**



Original Research Critical Care


# Mechanical Ventilation and ARDS in the ED: A Multicenter, Observational, Prospective, Cross-sectional Study

Brian M. Fuller MD<sup>a,b</sup>  , Nicholas M. Mohr MD<sup>d</sup>, Christopher N. Miller MD<sup>e</sup>,  
Andrew R. Deitchman MD<sup>f</sup>, Brian J. Levine MD<sup>f</sup>, Nicole Castagno MS<sup>g</sup>,  
Elizabeth C. Hassebroek MD<sup>h</sup>, Adam Dhedhi BA<sup>i</sup>, Nicholas Scott-Wittenborn BA<sup>j</sup>, Edward Grace<sup>k</sup>,  
Courtney Lehew MD<sup>a</sup>, Marin H. Kollef MD, FCCP<sup>c</sup>



## CONCLUSIONS

Lung-protective ventilation is infrequent in patients receiving mechanical ventilation in the ED, regardless of ARDS status. Progression to ARDS is common after admission, occurs early, and worsens outcome. Patient- and treatment-related factors present in the ED are associated with ARDS. Given the limited treatment options for ARDS, and the early onset after admission from the ED, measures to prevent onset and to mitigate severity should be instituted in the ED.



## CRITICAL CARE PERSPECTIVE

FIFTY YEARS OF RESEARCH IN ARDS

### Spontaneous Breathing during Mechanical Ventilation Risks, Mechanisms, and Management

Takeshi Yoshida<sup>1,2,3,4</sup>, Yuji Fujino<sup>4</sup>, Marcelo B. P. Amato<sup>5</sup>, and Brian P. Kavanagh<sup>1,2,3</sup>

<sup>1</sup>Translational Medicine, <sup>2</sup>Department of Critical Care Medicine, and <sup>3</sup>Department of Anesthesia, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; <sup>4</sup>Intensive Care Unit, Osaka University Hospital, Suita, Japan; and <sup>5</sup>Laboratório de Pneumologia LIM-09, Disciplina de Pneumologia, Heart Institute (InCor) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Recommendation:  
**Spontaneous breathing + controlled breathing  
with (pharmacologically-induced) muscle  
paralysis**

# Personalized Mechanical Ventilation in ARDS

1



## RATIONALE

Regulate ventilatory parameters based on close monitoring of targeted physiologic variables, intervention responses and individual integrated goals.

2



## TIDAL VOLUME

Low  $V_T$  (4-6 ml/Kg PBW) is a standard of care. Personalized targeting requires evaluation of EELV and IC, AI and closed-loop systems may provide better monitoring.


3



## DRIVING AND PLATEAU PRESSURE

Low  $\Delta P$  ( $< 13$  cmH<sub>2</sub>O) is a target in most patients.  $\Delta P$  could help individualize  $V_T$  and PEEP levels.  $P_{PLAT}$  should be kept below 27 cmH<sub>2</sub>O.

4



## TRANSPULMONARY PRESSURE

$P_L$  estimated on esophageal pressure can be used to titrate ventilation, but requires correct physiological interpretation.

5



## MECHANICAL POWER

Mechanical power is a summary variable including recognized determinants of VILI.

6



## ALVEOLAR RECRUITMENT

The identification of recruitable patients and estimation of recruitment are essential to individualize recruitment strategies.

7



## GAS-EXCHANGE

Gas-exchange including oxygenation is commonly targeted to set ventilation. However, dead space, ventilatory ratio and oxygen transport should be considered.

8



## LUNG IMAGING

Computed tomography remains the gold standard. Lung ultrasound and electrical impedance tomography are promising bedside tools.

9



## PHENOTYPES

Patient stratification according to biological phenotypes is promising, but translation into clinical practice requires further research.

10



## LIMITS OF PHYSIOLOGICAL GAIN

When applying physiological manipulations, clinicians should consider the uncertainty surrounding their effect on patient-centered outcomes

- 1) **Classify** severity
- 2) Monitor and **maintain**  $V_t$ ,  $P_{plat}$ , and  $\Delta P$
- 3) Implement/exploit **PEEP**
- 4) Utilize **recruitment maneuvers**
- 5) In certain cases, implement **paralyzation**
- 6) **Decrease MV support** when possible
- 7) Use **prone positioning**
- 8) Consider non-traditional **rescue therapies** as available (i.e., artificial lung, iNO)
- 9) Consider **ECMO**
- 10) **Wean PPV** when possible



Review  
Ten golden rules for individualized mechanical ventilation in acute respiratory distress syndrome  
Denise Battaglini<sup>1,2,#</sup>, Marco Sottano<sup>1,3,#</sup>, Lorenzo Ball<sup>1,3</sup>, Chiara Robba<sup>1,3</sup>,  
Patricia R.M. Rocco<sup>4</sup>, Paolo Pelosi<sup>1,3,\*</sup>

<sup>1</sup> Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, Genoa 16132, Italy  
<sup>2</sup> Department of Medicine, University of Barcelona, Barcelona 08007, Spain  
<sup>3</sup> Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa 16126, Italy  
<sup>4</sup> Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil

# ARDS-related complications

Barotrauma

Nosocomial infection (VAP/VAE)

Delirium

Thrombi

GI bleeding


Sleep disturbances




Poor nutrition

**Multiorgan failure**

## KEEP THE DRIVING PRESSURE LOW

matches tidal volume to available lung  
reduces lung stress and strain






Ventilate  
This!



# Variables of PPV

- ❖ Flow
- ❖ Pressure
- ❖ Volume
  
- ❖ Time





Flow & Volume

# Old Process, New Method



# Equation of Motion

$$P_{\text{VENT}} + P_{\text{MUSC}} = (E \times V) + (R \times V)$$

$P_{\text{vent}}$  – pressure generated by ventilator > PEEP


$P_{\text{musc}}$  – pressure generated by inspiratory muscles

- ❖ E – respiratory system elastance
- ❖ V –  $\Delta$  lung volume above FRC
  
- ❖ R – respiratory system resistance
- ❖ V - flow

# Factors to “Overcome”

- ❖ Airways resistance ( $R_{aw}$ )
- ❖ Lung Compliance ( $C_L$ )
- ❖ Elasticity
- ❖ Thoracic Wall

$$V = \Delta P r^4 \pi / 8 l \eta$$




# Time Constant ( $\tau$ )

$$1 \text{ TC} = C_L \times R_{aw}$$

How quickly pressure equilibrates between circuit & alveoli

3-to-5-time constants required for complete inspiration/expiration





**What about ventilator  
mode...**

**Volume-targeted or**

**Pressure-targeted?**

# Pressure-Controlled vs Volume-Controlled Ventilation in Acute Respiratory Failure

## A Physiology-Based Narrative and Systematic Review

*Nuttapol Rittayamai, MD; Christina M. Katsios, MD; François Beloncle, MD; Jan O. Friedrich, MD, PhD; Jordi Mancebo, MD; and Laurent Brochard, MD*

**CONCLUSIONS:** The two modes have different working principles but **clinical available data do not suggest any difference in the outcomes**. We included all identified trials, enhancing generalizability, and attempted to include only sufficient quality physiologic studies. However, included trials were small and varied considerably in quality. These data should help to open the choice of ventilation of patients with acute respiratory failure. CHEST 2015; 148(2):340-355

[Intervention Review]

## **Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS)**

Binila Chacko<sup>1</sup>, John V Peter<sup>1</sup>, Prathap Tharyan<sup>2</sup>, George John<sup>1</sup>, Lakshmanan Jeyaseelan<sup>3</sup>

### **Authors' conclusions**

Currently available data from RCTs are insufficient to confirm or refute whether pressure-controlled or volume-controlled ventilation offers any advantage for people with acute respiratory failure due to acute lung injury or acute respiratory distress syndrome. More studies including a larger number of people given PCV and VCV may provide reliable evidence on which more firm conclusions can be based.

# Biotrauma and Ventilator-Induced Lung Injury

## Clinical Implications



Gerard F. Curley, MB, PhD; John G. Laffey, MD; Haibo Zhang, MD, PhD; and Arthur S. Slutsky, MD

Summary:

**Ventilator = Bad**

***Suggestions for avoiding VILI:***


Lung protective strategies (higher PEEP, lower Vt),  
Prone positioning, NMBA, ECMO

RESEARCH

Open Access

# Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study




Etienne Gayat<sup>1,28\*</sup> , Alain Cariou<sup>2</sup>, Nicolas Deye<sup>3</sup>, Antoine Vieillard-Baron<sup>4</sup>, Samir Jaber<sup>5</sup>, Charles Damoiseil<sup>1</sup>, Qin Lu<sup>6</sup>, Xavier Monnet<sup>7</sup>, Isabelle Rennuit<sup>8</sup>, Elie Azoulay<sup>9</sup>, Marc Léone<sup>10</sup>, Heikel Oueslati<sup>1</sup>, Bertrand Guidet<sup>11</sup>, Diane Friedman<sup>12</sup>, Antoine Tesnière<sup>13</sup>, Romain Sonnevill<sup>14</sup>, Philippe Montravers<sup>15</sup>, Sébastien Pili-Floury<sup>16</sup>, Jean-Yves Lefrant<sup>17,18</sup>, Jacques Duranteau<sup>19</sup>, Pierre-François Laterre<sup>20</sup>, Nicolas Brechot<sup>21</sup>, Karine Chevreul<sup>22</sup>, Morgane Michel<sup>23</sup>, Bernard Cholley<sup>24</sup>, Matthieu Legrand<sup>1</sup>, Jean-Marie Launay<sup>24</sup>, Eric Vicaut<sup>25</sup>, Mervyn Singer<sup>26</sup>, Matthieu Resche-Rigon<sup>27†</sup> and Alexandre Mebazaa<sup>1†</sup>

**Results:** Of 1570 patients discharged alive from the ICU, 333 (21%) died over the following year. Multivariable analysis identified age, comorbidity, red blood cell transfusion, ICU length of stay and abnormalities in common clinical factors at the time of ICU discharge (low systolic blood pressure, temperature, total protein, platelet and white cell count) as independent factors associated with 1-year mortality. Elevated biomarkers of cardiac and vascular failure independently associated with 1-year death when they are added to multivariable model, with an almost 3-fold increase in the risk of death when combined (adjusted odds ratio 2.84 (95% confidence interval 1.73–4.65),  $p < 0.001$ ).





**Conclusions:** The FROG-ICU study identified, at the time of ICU discharge, potentially actionable clinical and biological factors associated with poor long-term outcome after ICU discharge. Those factors may guide discharge planning and directed interventions.

**Trial registration:** ClinicalTrials.gov NCT01367093. Registered on 6 June 2011.





AP ERECT MOBILE

**“Ventilator Mismanagement Sign”**



*Froese (1997), Crit Care Med. 25(6)*





# Generally speaking,...

- ❖ End-inspiratory **plateau pressure** and **Vt/IBW** ratio are inadequate surrogates to qualify and/or quantify end-inspiratory stress and strain<sup>1</sup>
- ❖ Large static strains are less harmful than large dynamic strains<sup>2</sup>
- ❖ An optimal “protective breath” describes one of minimal dynamic strain and energy/power load<sup>3</sup>
- ❖ Lung protection > diaphragm protection<sup>4</sup>

1. Gattinoni et. al. *Current Opinion in Critical Care* 18 (1), 2012.

2. Protti et. al. *Critical Care Medicine* 41 (4), 2013.

3. Nieman, et. al. *Intensive Care Medicine Experimental* 4 (16), 2016.

4. Goligher et. al. *AJRCCM* 202 (7). 2020

# Summary

- **Lung protective** ventilation is a must
    - Lower tidal volumes
  - Application of optimal (and *adequate*) **PEEP** may require higher than traditional settings
  - Target **low** plateau **pressure** (and low driving pressure)
  - Use **recruitment maneuvers** cautiously
  - Consider **prone** positioning
  - Seek to maintain **ventilator synchrony** – may require neuromuscular blockade
- \*\*\*Don't disregard potential **non-traditional intervention** as an effective option: NIV, HFOV, APRV, ECMO, etc.

Thanks for Listening!



[tim.gilmore@lsuhs.edu](mailto:tim.gilmore@lsuhs.edu)